Comparison of the Efficacy, Tolerability and Safety of actiTENS to Those of Level 2 Analgesic Treatments.

Knee Osteoarthritis Clinical Trial

— ArthroTENS  

Official title:

Multicentre, Phase 3, Prospective Study With On-line Randomization, in Single Blind Conditions for the Primary Efficacy Endpoint, Controlled, in Two Parallel Groups, Comparing the Efficacy, Tolerability and Safety of actiTENS Versus Level 2 Systemic Analgesics Recommended for the Treatment of Chronic Nociceptive Pain of Moderate to Severe Intensity in Patients Suffering From Osteoarthritis of the Knee

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03902340
• Other study ID #: 2018-A01895-50
• Status: Recruiting
• Phase: N/A
• Start date: December 19, 2018
• Est. completion date: October 31, 2019

Study information

• Verified date: April 2019
• Source: Sublimed
• Contact: Patricia Abraham Briffod
• Phone: +33 4 76 37 17 58
• Email: contact[@]subli-med.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase 3, multicentre, prospective, single-blind on principal efficacy criterion, 2 parallel groups, randomized, controlled clinical study comparing efficacy and safety of actiTENS versus systemic level 2 analgesics recommended for the treatment of moderate or severe, nociceptive, chronic pain in patients suffering from osteoarthritis of the knee.

Description:

Osteoarthritis (OA) is a debilitating chronic condition requiring long-term treatment of pain and inducing functional impairment. More specifically knee osteoarthritis (KOA) is a common disease associated with significant morbidity. Its prevalence increases with age dramatically. KOA is frequently associated with pain which can worsen with daily activities. The goals of KOA treatments are to provide pain relief and to improve function and quality of life. For the American college of Rheumatology and despite the frequent use of TENS in treating patients with KOA, questions remained regarding its efficacy. Consequently TENS needs additional clinical studies to demonstrate its efficacy in management of painful osteoarthritis.

The main objective of this study is to demonstrate the efficacy and to the safety of TENS in the management of chronic, nociceptive pain in patient suffering from KOA.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 110
• Est. completion date: October 31, 2019
• Est. primary completion date: June 30, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Adult > or = 55 years.

• Being monitored by a rheumatologist in private practice or in a hospital.

• Presenting nociceptive pain:

• chronic (for at least 3 months),

• secondary to knee osteoarthritis confirmed by x-ray: stage 2 and over according to Kellgren and Lawrence.

• Of moderate to severe intensity equal to or above 4 on a numerical scale of 0-10.

• In a situation of analgesic therapy failure for level 1 analgesics:

• paracetamol and NSAIDS,

• Prescribed at therapeutic dose : 4 g/d of paracetamol and 1200 mg/d of ibuprofen or equivalent (analgesic dose),

• For at least 2 weeks,

• Requiring a level 2 prescription.

• Affiliated to social security insurance.

• Informed of the concept and agreeing to use the TENS as a non-medicinal analgesic treatment.

• Capable of understanding how to use the TENS and the level 2 analgesic treatments.

• Intellectually and physically able to participate in the study in the opinion of the investigator.

• Owns a Smartphone to be able to download the actiTENS application.

Exclusion Criteria:

• Current or previous allergy to the actiTENS electrodes.

• On-going or planned pregnancy and absence of effective contraception (except for menopausal women).

• Neuropathic pain with a DN4 result > 4/10 or with a positive response to one or more questions in the DN4 clinical examination.

• Osteoarthritis flare.

• Surgery planned in the following 6 months.

• History of multiple operations on the knee concerned.

• Medicinal or non-medicinal treatments which could influence the pathology being studied.

• Modification of medicinal or non-medicinal treatments planned in the following 6 months.

• Current participation in another study.

• Presence of another painful condition which could perturb the evaluation.

• Patient with an absolute contraindication to TENS or level 2 systemic analgesic treatments recommended for the treatment of chronic pain of moderate or severe intensity.

• Patient unable to express his/her consent or deprived of liberty.

• Patient with cognitive disorder or behaviour rendering him/her unsuitable to follow the instructions for this study.

• Patient not affiliated to a social security system.

Related Conditions & MeSH terms

• Knee Osteoarthritis
• Nociceptive Pain
• Osteoarthritis
• Osteoarthritis, Knee

Intervention

Device:
• ActiTENS
ActiTENS is a rechargeable box, weighing 64g attached by Velcro to an adhesive support, which can be positioned on the skin at any position chosen by the patient. The patient will use the programme (P4) prescribed by his doctor and will regulate the intensity of stimulation using an application downloaded to his smartphone which will communicate with the box via Bluetooth.

Drug:
• Level 2 Analgesic Treatments
There are 4 level 2 oral analgesic treatments indicated for chronic nociceptive pain of moderate to severe intensity (between 4 and 7 on a simple numerical scale of 11 points) (12): Tramadol immediate release formulation (IR, one intake every 6 hours) or prolonged release formulation (PR, one intake every 12 hours); maximum posology 400mg/24h. Dihydrocodeine: 60mg every 12 hours; maximum posology 120mg/24h. Combination of paracetamol and codeine in a fixed combination every 6 hours; maximum posology of codeine: 300mg/24h. Combination of paracetamol and tramadol in a fixed combination; maximum posology of tramadol: 8 tablets/24h ie 300mg/24h.

Locations

Country	Name	City	State
France	Hôpital Roger Salengro	Lille

Sponsors (2)

Lead Sponsor	Collaborator
Sublimed	Eurofins Optimed

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy : pain intensity evaluated by a numerus scale from 0 to 10	Pain intensity (PI) at M3 between both treatment groups. Numerus scale with a minimum of 0 (no pain) to a maximum of 10 (maximum pain).	3 months after dosing
Primary	Safety : occurence of adverse events	Number of adverse events (AE) occurred during the 3 months of follow-up and due to studied treatments.	3 months after dosing
Secondary	Efficacy : pain intensity evaluated by a numerus scale from 0 to 10	Minimum, maximum,median and difference of pain intensity (PI) during movement and at rest at M1, M3 and M6 between both treatment groups	1, 3 and 6 months after dosing
Secondary	Efficacy : functional status evaluated by the WOMAC score (Western Onatario McMaster score)	Functional status (pain, function, stiffness) at M1, M3 and M6.	1, 3 and 6 months after dosing
Secondary	Efficacy : pain relief (PAR) evaluated by the pain visual analogue scale (VAS)	Pain relief at M1, M3 and M6. VAS from 0 to 10 with 0 = no relief and 10 = total relief). Scale of 100 mm.	1, 3 and 6 months after dosing
Secondary	Efficacy : quality of life evaluated by the questionnaire EuroQol-5D	Evaluation of the quality of life at M1, M3 and M6	1, 3 and 6 months after dosing
Secondary	Efficacy : patient global impression of change evaluated by a global impression questionnaire.	Evaluation of the change on activity, symptoms, emotions, quality of life regarding the pain of patient at M1, M3 and M6	1, 3 and 6 months after dosing
Secondary	Efficacy : drop-outs for inefficacy	Evaluation of the number of patient drop outs because of treatment inefficacy in each arm	Through study completion, an average of 6 months
Secondary	Efficacy : prolongation of studied treatment	Evaluation of the number of patient wishes to continue the studied treatment.	Through study completion, an average of 6 months
Secondary	Safety : occurrence of Adverse Events (AE)	Evaluation by the type of AE and the date of occurence	Through study completion, an average of 6 months
Secondary	Safety : drop-outs for AE and corrective treatments	Evaluation of the number of patient drop outs because of the occurence of adverse events in each arm	Through study completion, an average of 6 months
Secondary	Estimation of direct costs.	Comparison of treatment costs between the two arms	Through study completion, an average of 6 months